Effect of tumour necrosis factor alpha in vivo on human granulocyte oxidative metabolism.
Tumour necrosis factor alpha (TNF alpha) effectively stimulates the oxidative metabolism of human PMN in vitro. Moreover, preincubation of PMN with TNF alpha has been shown to result in an altered response of the target cells to subsequent stimulation. In the present study the response of PMN to stimulation in vitro was investigated in patients with metastasizing malignant melanoma receiving bolus injections of recombinant human TNF alpha as therapy. TNF alpha was given daily for 5 days. Blood samples were taken prior to TNF alpha administration on days 1 to 4 and on day 8. Lucigenin-enhanced chemiluminescence (CL) was used as a sensitive measure of granulocyte oxidative metabolism. PMN were stimulated with TNF alpha, TNF beta, GM-CSF, PMA, opsonized zymosan and f-met-leu-phe. A significant increase in CL responses was detected upon stimulation with TNF alpha, TNF beta and PMA from day 1 to day 3, whereas no significant changes were observed for the background activity or when GM-CSF or opsonized zymosan were used as stimuli. On day 4 all CL responses returned to the day 1 starting level. A further significant decrease was observed on day 8 upon stimulation with TNF alpha, TNF beta and GM-CSF. In contrast, the effect induced by f-met-leu-phe reached a maximum on day 4, but the CL response was found to be at the starting level on day 8. The results indicate that TNF alpha induces significant changes in PMN response to distinct stimuli in vivo. Moreover, it may be possible that continuous daily infusions with TNF alpha induce a hyposensitization of PMN oxidative metabolism.
Kapp
A
A
Department of Dermatology, University of Freiburg, Federal Republic of Germany.
Komann
A
A
Schöpf
E
E
D000166:Acridines; D000595:Amino Acid Sequence; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006801:Humans; D008163:Luminescent Measurements; D008233:Lymphotoxin-alpha / Q000494:pharmacology; D008545:Melanoma / Q000378:metabolism / Q000556:secondary; D008969:Molecular Sequence Data; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D010084:Oxidation-Reduction; D011994:Recombinant Proteins / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D015054:Zymosan / Q000494:pharmacology
D000166:Acridines; D008233:Lymphotoxin-alpha; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; C033472:10,10'-dimethyl-9,9'-biacridinium; D009240:N-Formylmethionine Leucyl-Phenylalanine; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D015054:Zymosan; D013755:Tetradecanoylphorbol Acetate